Nyrada Inc
NYR
Company Profile
Business description
Nyrada Inc is a clinical-stage biotechnology company focused on the discovery and development of small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. Its flagship candidate, Xolatryp, is being developed for applications in cardioprotection and neuroprotection. The company operates in one segment being research and development of drugs focusing on small molecules with potential therapeutic benefit in areas of medical need and it operates in one geographical area being Australasia.
Contact
180 George Street, Sydney Place
Level 22/23, Salesforce Tower
SydneyNSW2000
AUST: +61 294983390
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
stocks
Apple earnings: A smooth transition despite continued memory and supply headwinds
Shares fell as investors digested the latest earnings.
stocks
Two new ASX names added to our Global Best Stock Ideas
Our full global list includes 78 companies from around the world.
stocks
Big four bank holds up in weakening economic conditions
Major bank earnings hold up in challenging conditions.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,972.30 | 36.60 | -0.41% |
| CAC 40 | 8,020.31 | 27.38 | -0.34% |
| DAX 40 | 25,864.62 | 116.47 | -0.45% |
| Dow JONES (US) | 51,786.72 | 197.26 | -0.38% |
| FTSE 100 | 10,638.43 | 122.90 | -1.14% |
| HKSE | 23,525.97 | 132.65 | 0.57% |
| NASDAQ | 25,372.01 | 207.65 | 0.83% |
| Nikkei 225 | 62,899.21 | 182.65 | -0.29% |
| NZX 50 Index | 13,738.03 | 17.77 | 0.13% |
| S&P 500 | 7,568.92 | 27.52 | 0.36% |
| S&P/ASX 200 | 8,844.30 | 42.50 | -0.48% |
| SSE Composite Index | 3,608.10 | 29.93 | -0.82% |